SG Americas Securities LLC boosted its stake in shares of Regenxbio Inc (NASDAQ:RGNX) by 1,746.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 179,279 shares of the biotechnology company’s stock after acquiring an additional 169,571 shares during the quarter. SG Americas Securities LLC owned approximately 0.49% of Regenxbio worth $10,274,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the business. Berman Capital Advisors LLC acquired a new position in Regenxbio during the 4th quarter valued at about $33,000. Financial Gravity Wealth Inc. acquired a new position in Regenxbio during the 1st quarter valued at about $55,000. NumerixS Investment Technologies Inc acquired a new position in Regenxbio during the 4th quarter valued at about $50,000. LS Investment Advisors LLC lifted its position in Regenxbio by 63.1% during the 4th quarter. LS Investment Advisors LLC now owns 2,260 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 874 shares during the period. Finally, Meeder Asset Management Inc. lifted its position in Regenxbio by 31.7% during the 4th quarter. Meeder Asset Management Inc. now owns 2,578 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 621 shares during the period. 83.11% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Curran Simpson sold 5,300 shares of the stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $54.05, for a total transaction of $286,465.00. Following the completion of the sale, the senior vice president now directly owns 44,800 shares of the company’s stock, valued at approximately $2,421,440. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kenneth T. Mills sold 15,000 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $58.53, for a total value of $877,950.00. Following the sale, the chief executive officer now directly owns 261,000 shares of the company’s stock, valued at $15,276,330. The disclosure for this sale can be found here. Insiders sold a total of 70,368 shares of company stock worth $3,728,946 over the last quarter. 13.80% of the stock is currently owned by corporate insiders.
Shares of NASDAQ:RGNX traded down $0.38 during mid-day trading on Wednesday, reaching $42.62. The stock had a trading volume of 395,197 shares, compared to its average volume of 534,333. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of 17.91 and a beta of 0.37. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.21 and a quick ratio of 14.21. Regenxbio Inc has a twelve month low of $38.56 and a twelve month high of $85.10.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.04). The firm had revenue of $0.88 million during the quarter. Regenxbio had a negative net margin of 41.99% and a negative return on equity of 9.90%. Equities research analysts expect that Regenxbio Inc will post -3.21 earnings per share for the current year.
RGNX has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Regenxbio from a “hold” rating to a “buy” rating and set a $51.00 target price on the stock in a research report on Tuesday, January 22nd. ValuEngine upgraded shares of Regenxbio from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. TheStreet downgraded shares of Regenxbio from a “c” rating to a “d+” rating in a research report on Thursday, May 9th. Finally, BidaskClub upgraded shares of Regenxbio from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Regenxbio has an average rating of “Buy” and an average price target of $78.72.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Sundance Herald and is owned by of Sundance Herald. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://sundanceherald.com/2019/05/22/sg-americas-securities-llc-has-10-27-million-position-in-regenxbio-inc-rgnx.html.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Read More: What is Elliott Wave theory?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.